Compare Invesco DB Commodity Index Tracking Fund (DBC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs GSK plc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.94 (market cap $1.92B), while GSK plc trades at $46.6 (market cap $91.88B). The key difference: GSK plc is far larger — about 47.9× Invesco DB Commodity Index Tracking Fund's market cap, and GSK plc pays a 3.9% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and GSK plc for 93 Days on average.
| DBC | GSK | |
|---|---|---|
Market Cap | $1.92B | $91.88B |
Volume | 1,375,556 | 7,730,529 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $61.18 |
52-Week Low | $22.07 | $43.24 |
Typical Hold Time | 60 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
